The research-context dosing references for each compound live on their respective protocol pages: the BPC-157 10 mg vial research dosage reference and the TB-500 10 mg vial research dosage reference
Synergistic Convergence Here's the bottom line on why this combo makes sense: BPC-157 handles the local work fixing up blood flow, pumping out growth factors, and getting cells to stick where they need to at the injury site
The two act through complementary repair routes BPC-157 drives local angiogenesis and growth-factor signalling, while TB-500 promotes cell migration and actin regulation which is why recovery studies frequently run them together
In addition to excessive intake of dietary supplements, parenteral administration of vitamin B12 may be another cause of excess, which is likely associated with an immune system response to produce anti-TC II antibodies
Prescription peptides used under medical supervision have generally favorable safety profiles in published research, though risks vary by peptide, dose, and your individual health context
Oral BPC-157 is used primarily for gut health applications
